2009 Vol. 11, No. 11 2421–2424

## Biselyngbyaside, a Macrolide Glycoside from the Marine Cyanobacterium *Lyngbya* sp.

Toshiaki Teruya,<sup>†</sup> Hiroaki Sasaki,<sup>†</sup> Kazuhiro Kitamura,<sup>†</sup> Takeshi Nakayama,<sup>‡</sup> and Kiyotake Suenaga<sup>†,\*</sup>

Department of Chemistry, Faculty of Science and Technology, Keio University, Hiyoshi 3-14-1, Kohoku-ku, Yokohama 223-8522, Japan, and Institute of Biological Sciences, University of Tsukuba, Tsukuba, Ibaraki 305-8572, Japan

suenaga@chem.keio.ac.jp

Received March 20, 2009

## **ABSTRACT**

biselyngbyaside 1

Bioassay-guided fractionation of the cytotoxic constituents of the marine cyanobacterium *Lyngbya* sp. led to the isolation of biselyngbyaside (1), a new 18-membered macrolide glycoside. The structure of 1 was established by spectroscopic analysis including 2D-NMR techniques and by synthetic studies. Biselyngbyaside (1) exhibits broad-spectrum cytotoxicity in a human tumor cell line panel.

The oceans are a good source of new biologically active substances. Over the past few decades, a considerable number of marine natural products have been reported. Several compounds that are now used at the clinical trial level, such as halichondrin B, bryostatin 1, and dolastatin 10, were originally found in marine animals. Therefore, marine natural products continue to receive increasing attention. In particular, cyanobacteria are prolific producers of bioactive secondary metabolites.

In our ongoing efforts to identify novel marine cyanobacterial metabolites with antitumor activity, we found biselyngbyaside (1). Over the past few years, several classes of

† Keio University.

<sup>‡</sup> University of Ťsukuba.


macrolides have been isolated from marine sponges. These include 18-membered macrolides, tedanolide<sup>9</sup> and 13-deoxytedanolide<sup>9</sup> from *Tedania ignis* and *Mycale adhaerens*, respectively, laulimalide, a 20-membered ring from *Cacospongia mycofijiensis*, *Hyatella* sp., *Fasciospongia* sp., *Dactylospongia* sp., and a chromodorid nudibranch, and peloruside A, a 16-membered ring macrolide from *Mycale hentscheli*. Biselyngbyaside (1) has the same macrolide ringsize as tedanolide and 13-deoxytedanolide. We report here the isolation, structure determination, and biological activity of 1.

The marine cyanobacterium Lyngbya sp. (a voucher specimen was deposited at Keio University), collected in Okinawa Prefecture, was extracted with methanol. The concentrated extract was partitioned between ethyl acetate and water, and the ethyl acetate layer was concentrated and partitioned between n-hexane and 90% aqueous methanol. The concentrated 90% aqueous methanol layer was subjected to fractionation guided by cytotoxicity against HeLa  $S_3$  cells

<sup>(1)</sup> Blunt, J. W.; Copp, B. R.; Hu, W.-P.; Munro, H. H. G.; Northcote, P. T.; Prinsep, M. R. *Nat. Prod. Rep.* **2009**, *26*, 170–244.

<sup>(2)</sup> Molinski, T. F.; Dalisay, D. S.; Lievens, S. L.; Saludes, J. P. *Nat. Rev. Drug Discovery* **2009**, *8*, 69–85.

<sup>(3) (</sup>a) Uemura, D.; Takahashi, K.; Yamamoto, T.; Katayama, C.; Tanaka, J.; Okumura, Y.; Hirata, Y. *J. Am. Chem. Soc.* **1985**, *107*, 4796–4798. (b) Hirata, Y.; Uemura, D. *Pure Appl. Chem.* **1986**, *58*, 701–710.



**Figure 1.** Gross structure of **1** determined by 2D-NMR spectroscopy (bold lines,  ${}^{1}H-{}^{1}H$  COSY; arrows, HMBC correlations).

with column chromatography (ODS silica gel, methanol—water) and reversed-phase HPLC to give biselyngbyaside (1) as a colorless oil. Biselyngbyaside (1) exhibited cytotoxicity against HeLa  $S_3$  cells (IC<sub>50</sub> = 0.1  $\mu$ g/mL).

The molecular formula of 1 was determined to be  $C_{34}H_{52}O_{9}$ by ESIMS  $[(M + Na)^+, m/z 627.3487, \Delta - 2.2 \text{ mmu}]$ . The IR spectrum contained absorption bands for hydroxyl and ester groups [3589, 3502 (br), 1725 cm<sup>-1</sup>]. The NMR data for 1 are summarized in Table 1. The <sup>1</sup>H NMR spectrum of 1 showed the presence of six methyl groups ( $\delta$  3.62, 3.15, 1.67, 1.64, 1.55, and 1.02). In the <sup>13</sup>C NMR spectrum, 34 carbon signals were observed, including one carbonyl carbon  $(\delta 172.1)$ , 12 olefinic carbons  $(\delta 140.1, 138.4, 135.3, 133.3,$ 133.0, 132.7, 132.1, 131.9, 129.3, 127.9, 127.4, and 124.9), and six methyl carbons ( $\delta$  61.0, 55.6, 23.6, 22.5, 18.1, and 10.2). The remaining carbon signals were assigned to six methylenes and nine methines, based on the results of an HMQC experiment. The presence of a 3-O-methylglucoside moiety in 1 was readily revealed based on the coupling constants in the <sup>1</sup>H NMR spectra (Figure 1) and correlations in the  ${}^{1}H-{}^{1}H$  COSY spectra, and their  $\beta$ -anomeric structures were determined by correlations in the NOESY spectrum (H1'/H3' and H1'/H5') and the  ${}^{1}J_{CH}$  value at the anomeric carbons ( $\delta_{Cl'}$  160 Hz). This result was also supported by the <sup>1</sup>H NMR spectrum, where the magnitude of  ${}^{3}J_{\mathrm{H}1'-2'}$  was 7.8 Hz as measured in CD<sub>3</sub>OD. Regarding the macrolide moiety, three sets of proton spin systems, C2-C7, C9-C18, and C20-C23, were determined based on the <sup>1</sup>H-<sup>1</sup>H COSY spectrum. The connectivities between these partial structures

Table 1. NMR Spectral Data of 1 in CD<sub>3</sub>OD

	1	- 5-	
position	$^{1}\mathrm{H}~(\mathrm{ppm})^{a}$	$^{13}\mathrm{C}~(\mathrm{ppm})^b$	$\mathrm{HMBC}^c$
1		172.1	H-2, 3, 17
2a	2.32 m	42.9	
2b	2.57 dd (14.7, 7.8)		
3	4.50 m	77.4	H-4, 1', 2a, 2b
4	5.42 m	131.9	H-3, 5
5	5.44 m	129.3	H-4, 6a, 6b
6a	2.31 m	36.8	H-7, 5
6b	2.32 m		
7	3.47 m	89.0	H-6a, 6b, 9, 24, 25
8		133.0	H-6, 7, 25
9	5.10 d (8.8)	138.4	H-7, 25, 26
10	2.68 m	34.0	H-9, 11a, 26
11a	1.94 m	41.5	H-9, 13, 26
11b	2.30 m		
12	5.55 m	133.3	H-11a
13	6.05 dd (17.6, 10.3)	135.3	
14	6.00 dd (17.6, 10.3)	132.1	
15	5.52 m	132.7	H-16a, 16b
16a	2.22 m	39.6	H-14, 15
16b	2.39 m		
17	5.51 m	72.0	H-1'
18	5.13 d (8.8)	124.9	H-20a, 20b, 27
19		140.1	H-20a, 20b
20a	2.72 dd (14.7, 5.9)	36.6	H-27, 18, 21
20b	2.92 dd (14.7, 6.8)		
21	5.40 m	127.9	H-20a, 20b, 23
22	5.50 m	127.4	H-20a, 20b, 23
23	1.64 d (5.9)	18.1	H-21, 22
24	$3.15 \mathrm{\ s}$	55.6	H-7
25	$1.55 \mathrm{\ s}$	10.2	H-7, 9
26	1.02 d (6.3)	22.5	
27	1.67 s	23.6	H-18, 20a, 20b
1'	4.25 d (7.8)	100.9	H-2'
2'	3.22 dd (9.3, 7.8)	74.5	H-1', 3', 4'
3′	3.04 dd (9.3, 9.3)	87.7	H-1', 2', 4', 7'
4'	3.44 dd (9.3, 8.8)	70.7	H-3'
5'	3.18 m	77.6	H-4'
6'a	3.73 dd (11.7, 4.4)	62.4	H-4'
6'b	3.85 dd (11.7, 2.0)		
7′	$3.62 \mathrm{\ s}$	61.0	H-3'

<sup>&</sup>lt;sup>a</sup> Recorded at 400 MHz. Coupling constants (Hz) are in parentheses. <sup>b</sup> Recorded at 100 MHz. <sup>c</sup> Protons correlated to carbon resonances in  $^{13}$ C column. Parameters were optimized for  $J_{\rm CH}=6$  Hz.

and the 3-O-methylglucoside moiety in **1** were clarified by HMBC correlations: H1'/C2, H25/C7, H25/C8, H25/C9, H27/C18, H27/C19, and H27/C20. HMBC correlations H2/C1 suggested the connectivity of C1–C2. Consequently, the entire carbon chain was assembled, and all protons and carbons were assigned, as shown in Figure 1 and Table 1, respectively. The HMBC correlations H24/C7, H7/C24, H7'/C3', and H3'/C7' determined that the two methoxy groups were located at C7 and C3'. On the basis of its molecular formula and degree of unsaturation, **1** should contain a lactone ring. Considering the chemical shift of H17 ( $\delta_{\rm H}$  5.51) and the HMBC correlation H17/C1, the lactone ring must be formed between C1 and C17. The double bond geometries in **1** were determined from proton—proton coupling constants and the NOE correlation from NOESY data as measured in

2422 Org. Lett., Vol. 11, No. 11, 2009


Scheme 1. Degradation Experiment of Biselyngbyaside (1)

 $C_6D_6$  (see Supporting Information). The geometries of the two trisubstituted olefins in  $\bf 1$  were clarified to be 8E and 18Z, respectively, based on the NOESY correlation of H25/H10, and H27/H18. The 4E, 12E, and 14E geometries were determined from the H4-H5, H12-H13, and H14-H15 *trans*-coupling constants (15.1, 16.6, and 16.6 Hz, respectively). In addition to these results, NOESY correlations were observed between H13 and H11, and between H14 and H16. A careful analysis of NOESY correlation observed between H21 and H23 revealed a 21E geometry. Thus, the gross structure of biselyngbyaside ( $\bf 1$ ) was determined to be as shown in Figure 1.

The absolute stereochemistries of C3, C17, and the 3-O-methylglucoside moiety in **1** were determined by the modified Mosher's method<sup>12</sup> and synthetic means. Methanolysis of **1** gave methyl ester **2** along with elimination of the sugar (Scheme 1). Since **1** is unstable under acidic and basic conditions, hydrogenation and subsequent acid hydrolysis provided 3-O-methylglucoside **5** and  $\beta$ -hydroxy methyl ester **6** accompanied by hydrogenolysis at C7 and C17 (Scheme 1). Derived products **2** and **6** were transformed into the (R)-and (S)-MTPA esters, **3** and **4**, and **7** and **8**, respectively (Scheme 1). The  $^{1}$ H NMR signals of these esters were

Chem. Soc. 1982, 104, 6846-6848.

assigned based on the 2D-NMR spectra, and the  $\Delta\delta$  values  $(\delta_S - \delta_R, Hz)$  were then calculated. These results established



**Figure 2.**  $\Delta\delta$  values ( $\Delta\delta_{S-R}$ ) in ppm for bis-S- and bis-R-MTPA esters (**3** and **4**, **7** and **8**).

that the absolute stereochemistries of C3 and C17 in **1** were 3*R* and 17*R*, respectively (Figure 2). Furthermore, tribromobenzoylation of **5** afforded methyl 2,4,6-tri-*O*-(4-bromobenzoyl)-3-*O*-methyl-α-D-glucose **9**, which was identified by <sup>1</sup>H NMR data and CD data (see Supporting Information). An authentic sample of **9** was prepared from D-glucose.

The absolute stereochemistries of C7 and C10 in 1 were determined by enantioselective synthesis of the degradation product from natural 1. The oxidative degradation of 1 into biscarbamates 10 was effected by a three-step sequence.

The synthesis of degradation product 10 started from known aldehyde 11a. The (2R)-aldehyde 11a was converted into aldehyde 12 in three steps. Treatment of 12 with

Org. Lett., Vol. 11, No. 11, 2009

<sup>(4)</sup> Pettit, G. R.; Herald, C. L.; Doubek, D. L.; Herald, D. L. J. Am.

<sup>(5)</sup> Pettit, G. R.; Kamano, Y.; Herald, C. L.; Tuiman, A. A.; Boettner, E. F.; Kizu, H.; Schmidt, J. M.; Baczynskyj, L.; Tomer, K. B.; Bontems, R. J. J. Am. Chem. Soc. **1987**, 109, 6883–6885.

<sup>(6) (</sup>a) Gerwick, W. H.; Tan, L. T.; Sitachitta, N. Alkaloids **2001**, *57*, 75–184. (b) Tan, L. T. *Phytochemistry* **2007**, *68*, 954–979.

<sup>(7)</sup> Schmitz, F. J.; Gunasekera, S. P.; Yalamanchili, G.; Bilayet Hossain, M.; Van Der Helm, D. *J. Am. Chem. Soc.* **1984**, *106*, 7251–7252.

<sup>(8)</sup> Fusetani, N.; Sugawara, T.; Matsunaga, S.; Hirota, H. J. Org. Chem. **1991**, *56*, 4971–4974.

<sup>(9) (</sup>a) Corley, D. G.; Herb, R.; Moore, R. E.; Scheuer, P. J. *J. Org. Chem.* **1988**, *53*, 3644–3646. (b) Jefford, C. W.; Bernadinelli, G.; Tanaka, J.; Higa, T. *Tetrahedron Lett.* **1996**, *37*, 159–162. (c) Mooberry, S. L.; Tien, G.; Hernandez, A. H.; Plubrukarn, A.; Davidson, B. S. *Cancer Res.* **1999**, *59*, 653–660.

<sup>(10) (</sup>a) West, L. M.; Northcote, P. T.; Battershill, C. N. *J. Org. Chem.* **2000**, *65*, 445–449. (b) Hood, K. A.; West, L. M.; Rouwe, B.; Northcote, P. T.; Berridge, M. V.; Wakefield. St., J.; Miller, J. H. *Cancer Res.* **2002**, *62*, 3356–3360.


<sup>(11)</sup> Bock, K.; Pedersen, C. J. Chem. Soc., Perk. Trans 2 1974, 293-

<sup>(12)</sup> Ohtani, I.; Kusumi, T.; Kashman, Y.; Kakisawa, H. J. Am. Chem. Soc. 1991, 113, 4092–4096.

<sup>(13)</sup> Pattenden, G.; Chattopadhyay, S. K. Tetrahedron Lett. 1995, 36, 5271-5274.

LiCH<sub>2</sub>COO'Bu gave a mixture of diastereomeric alcohols **13a** and **13b**, which was separated by silica gel column chromatography. The stereochemistries of the hydroxyl groups in **13a** and **13b** were determined by the modified Mosher's method. <sup>12</sup> Conversion of **13a** and **13b** into the respective biscarbamates **14a** and **14b** was achieved by a four-step sequence (Scheme 2). The <sup>1</sup>H NMR data of **14a** 

**Scheme 2.** Synthesis of Degradation Product of Natural Biselyngbyaside (1)



fully agreed with those of degradation product 10 from natural biselyngbyaside (1). To determine the absolute stereochemistry of 10, the enantiomeric (3R, 6R)-biscarbamate *ent*-14a was prepared from (2S)-aldehyde 11b in the same manner as described above, and both enantiomers were analyzed by chiral HPLC. Of the two synthetic enantiomers 14a and *ent*-14a, the retention time of *ent*-14a was identical to that for 10 from the natural product, which established the absolute stereochemistry of 10. Based on these findings, the complete stereostructure of biselyngbyaside (1) was determined as shown in 1.

Biselyngbyaside (1) exhibited cytotoxicity against HeLa  $S_3$  cells with an  $IC_{50}$  value of 0.1  $\mu g/mL$ . Biselyngbyaside (1) was evaluated against a disease-oriented panel composed of 39 human cancer cell lines (HCC panel) at the Japanese Foundation for Cancer Research (see Supporting Information). The average  $GI_{50}$  value across all of the cell lines tested was  $0.60~\mu M$ , and 1 exhibited differential cytotoxicities: the central nervous system cancer SNB-78 ( $GI_{50}$  0.036  $\mu M$ ) and lung cancer NCI H522 ( $GI_{50}$  0.067  $\mu M$ ) were especially sensitive. Biselyngbyaside (1) was COMPAREnegative, indicating that it likely inhibits cancer cell proliferation through a novel mechanism.

In summary, biselyngbyaside (1), with a potentially new mechanism of action, was isolated from the marine cyanobacterium *Lyngbya* sp. The structure of biselyngbyaside (1) was determined based on 2D-NMR spectra and synthetic procedures. Biselyngbyaside (1) exhibits broad-spectrum cytotoxicity in a human tumor cell line panel.

Acknowledgment. We thank Professor Isao Inoue (Univ. of Tsukuba) for identifying the cyanobacterium. We also thank Professor Hideo Kigoshi (Univ. of Tsukuba) for performing the ESIMS analysis. We thank Dr. T. Yamori (Screening Committee of Anticancer Drugs supported by Grant-in-Aid for Scientific Research on Priority Area "Cancer" from The Ministry of Education, Culture, Sports, Science and Technology, Japan) for screening in the human cancer cell line panel. This work was supported by a Grant-in-Aid for Young Scientists (B) from the Ministry of Education, Culture, Sports, Science and Technology, Jaoan, Keio Leading-edge Laboratory of Science and Technology, Keio Gijuku Academic Development Funds, and Suntory Institute for Bioorganic Research.

**Supporting Information Available:** Detailed experimental procedures, spectroscopic data and HCC panel data for **1**. This material is available free of charge via the Internet at http://pubs.acs.org.

OL900579K

2424 Org. Lett., Vol. 11, No. 11, 2009

<sup>(14)</sup> Yamori, T.; Matsunaga, A.; Sato, S.; Yamazaki, K.; Nakanishi, O.; Kohno, H.; Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. *Cancer Res.* **1999**, *59*, 4042–4049.